Helena Jernberg-Wiklund

List of Publications by Year
in descending order

25 papers	537 citations	759055 12 h-index	713332 21 g-index
25 all docs	25 docs citations	25 times ranked	1099 citing authors

#	Article	IF	Citations
1	A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death and Disease, 2021, 12, 167.	2.7	12
2	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. Epigenomes, 2021, 5, 22.	0.8	3
3	Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Therapy, 2020, 27, 948-959.	2.2	28
4	Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology, 2018, 51, 101-115.	4.3	59
5	Targeting EZH2 in Multiple Myelomaâ€"Multifaceted Anti-Tumor Activity. Epigenomes, 2018, 2, 16.	0.8	18
6	MBRS-42. GMYC: A NOVEL INDUCIBLE TRANSGENIC MODEL OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i137-i137.	0.6	1
7	The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA & Disease (Houston, Tex), 2017, 4, .	1.0	14
8	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget, 2017, 8, 10213-10224.	0.8	47
9	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget, 2017, 8, 103731-103743.	0.8	19
10	A Role for the Chromatinâ€Remodeling FactorBAZ1Ain Neurodevelopment. Human Mutation, 2016, 37, 964-975.	1.1	29
11	Growth signals employ CGGBP1 to suppress transcription of Alu-SINEs. Cell Cycle, 2016, 15, 1558-1571.	1.3	20
12	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget, 2016, 7, 6809-6823.	0.8	59
13	Functional loss of Iº Bμ leads to NF-ºB deregulation in aggressive chronic lymphocytic leukemia. Journal of Experimental Medicine, 2015, 212, 833-843.	4.2	85
14	CGGBP1 mitigates cytosine methylation at repetitive DNA sequences. BMC Genomics, 2015, 16, 390.	1.2	12
15	Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment. Oncotarget, 2015, 6, 20621-20635.	0.8	17
16	Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Upsala Journal of Medical Sciences, 2012, 117, 166-177.	0.4	4
17	The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Blood, 2012, 120, 1833-1833.	0.6	3
18	Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity. Blood, 2012, 120, 4010-4010.	0.6	0

#	Article	IF	Citations
19	ABT-737 Sensitizes B Cell Tumors for Killing by CD19-Retargeted T Cells,. Blood, 2011, 118, 4032-4032.	0.6	0
20	Polycomb Target Genes Are Silenced in Multiple Myeloma. PLoS ONE, 2010, 5, e11483.	1.1	81
21	Control of Apoptosis in Human Multiple Myeloma by Insulinâ€like Growth Factor I (IGFâ€I). Advances in Cancer Research, 2007, 97, 139-165.	1.9	12
22	Selective Inhibition of Glycogen Synthase Kinase-3 by Facilitators of Insulin Response Promotes Proliferation and Survival in Multiple Myeloma Cells.. Blood, 2007, 110, 4789-4789.	0.6	0
23	Expression of Erythropoietin Receptor (EPO-R) and In Vitro Functional Effects of Epoetin in B-Cell Malignancies.. Blood, 2005, 106, 4278-4278.	0.6	4
24	Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.. Blood, 2004, 104, 639-639.	0.6	2
25	Multiple Myeloma Cell Lines. , 2002, , 81-155.		8